Mitsubishi Tanabe Pharma Corporation
3-2-10, Dosho-machi, Chuo-ku
Osaka
541-8505
118 articles with Mitsubishi Tanabe Pharma Corporation
-
Mitsubishi Tanabe Pharma America Announces Nearly 4,000 ALS Patients in the U.S. Have Been Treated with RADICAVA ORS® (edaravone)
1/26/2023
Mitsubishi Tanabe Pharma America, Inc. announced that nearly 4,000 people with amyotrophic lateral sclerosis have received RADICAVA ORS® since the therapy became available in the U.S. in June 2022, and 79% of patients who started treatment with RADICAVA ORS or intravenous RADICAVA® between June 1, 2022 and September 30, 2022 have continued treatment for three months or more through December.
-
Mitsubishi Tanabe Pharma America Showcases Breadth of ALS Data at 21st Annual NEALS Meeting
11/1/2022
Mitsubishi Tanabe Pharma America, Inc. announced that six presentations on amyotrophic lateral sclerosis will be shared at the 21st Annual Northeast Amyotrophic Lateral Sclerosis Meeting, being held in Clearwater, Fla., from November 1-3.
-
EditForce and Mitsubishi Tanabe Pharma Enter into License Agreement
7/5/2022
EditForce, Inc. has entered into a License Agreement with Mitsubishi Tanabe Pharma Corporation to research, develop and commercialize potential gene therapy products for a specific target disease in the field of CNS by utilizing EditForce's proprietary PPR protein platform technology.
-
RADICAVA ORS® (edaravone) Now Available in the U.S. for the Treatment of ALS
6/15/2022
Mitsubishi Tanabe Pharma America, Inc. announced RADICAVA ORS® is now available in the United States for the treatment of amyotrophic lateral sclerosis, a neurodegenerative disease that currently has no cure and can progress rapidly.
-
The U.S. Food and Drug Administration (FDA) has approved Mitsubishi Tanabe Pharma America's oral alternative to its own treatment for amyotrophic lateral sclerosis (ALS).
-
Health Canada Accepts Snds Filing and Grants Priority Review for Oral Edaravone Formulation for the Treatment of ALS
5/13/2022
Mitsubishi Tanabe Pharma Canada, Inc., a subsidiary of Mitsubishi Tanabe Pharma America, Inc., announced that Health Canada has accepted the filing of a Supplement to a New Drug Submission for an investigational oral formulation of edaravone indicated for the treatment of amyotrophic lateral sclerosis.
-
Mitsubishi Tanabe Pharma America Announces FDA Approval of RADICAVA ORS® (edaravone) for the Treatment of ALS
5/13/2022
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the U.S. Food and Drug Administration (FDA) has approved RADICAVA ORS® .
-
The 2022 American Academy of Neurology (AAN) Annual Meeting kicked off on Saturday and will continue on through Thursday.
-
Mitsubishi Tanabe Pharma America to Showcase ALS Research at 2022 American Academy of Neurology Annual Meeting
4/1/2022
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced four presentations on amyotrophic lateral sclerosis (ALS) will be shared as part of the 2022 American Academy of Neurology Annual Meeting.
-
The FDA released materials for review ahead of Wednesday's meeting and it appears to paint a picture of insufficient data for approval, noting it is “not exceptionally persuasive.”
-
ADC Therapeutics Announces Exclusive License with Mitsubishi Tanabe Pharma Corporation to Develop and Commercialize ZYNLONTA® (loncastuximab tesirine-lpyl) in Japan
1/18/2022
ADC Therapeutics SA announced it has entered an exclusive license agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of ZYNLONTA® for all hematologic and solid tumor indications in Japan.
-
Mitsubishi Tanabe Pharma America Showcases Breadth of ALS Research at Virtual 32nd International Symposium on ALS/MND
12/1/2021
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced seven presentations on amyotrophic lateral sclerosis (ALS) as part of the Motor Neurone Disease Association (MNDA) 32nd International Symposium on ALS/MND, being held virtually December 7-10.
-
Mitsubishi Tanabe Pharma Canada Announces that Prince Edward Island has Added the Company's Treatment for Amyotrophic Lateral Sclerosis (ALS) to its Provincial Drug Formulary
11/23/2021
Mitsubishi Tanabe Pharma Canada, Inc., a subsidiary of Mitsubishi Tanabe Pharma America, Inc., announced that RADICAVA®, an infusion treatment for amyotrophic lateral sclerosis, is now reimbursed through Prince Edward Island Pharmacare under Special Authorization.
-
Mitsubishi Tanabe Pharma America Announces Presentations at 146th Annual Meeting of the American Neurological Association
10/15/2021
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that two abstracts on amyotrophic lateral sclerosis (ALS) will be presented during the 146th Annual Meeting of the American Neurological Association (ANA2021), being held virtually October 17-19 .
-
Mitsubishi Tanabe Pharma America Presents Analysis Examining Real-World Data on ALS Patient Disease Progression Milestones
4/20/2021
Mitsubishi Tanabe Pharma America, Inc. announced the presentation of an analysis of the timing of disease progression milestones among commercially insured amyotrophic lateral sclerosis patients treated with intravenous RADICAVA®.
-
Post-Hoc Analysis of Phase 3 Study Examines Effect of Early Intervention with Edaravone on Survival and Disease Progression Milestone Events in ALS Patients
3/18/2021
Mitsubishi Tanabe Pharma America, Inc. announced a post-hoc analysis of its Phase 3 edaravone study reviewing the results of intravenous edaravone treatment on disease progression milestones and events among people with amyotrophic lateral sclerosis.
-
Mitsubishi Tanabe Pharma America Presents Data on Impact of ALS Symptoms on Patients' Ability to Independently Conduct Daily Activities
3/17/2021
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced findings from a new analysis evaluating the impact of symptom progression on the ability of people with amyotrophic lateral sclerosis (ALS)
-
Mitsubishi Tanabe Pharma Canada Announces Treatment for Amyotrophic Lateral Sclerosis (ALS) is Now Available Through Newfoundland and Labrador Prescription Drug Program
3/10/2021
Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA), a subsidiary of Mitsubishi Tanabe Pharma America, Inc. (MTPA), announced today that RADICAVA ® (edaravone), an infusion treatment for amyotrophic lateral sclerosis (ALS), is now reimbursed through the Newfoundland and Labrador Prescription Drug Program (NLPDP) under Special Authorization.
-
Mitsubishi Tanabe Pharma America Announces Establishment of NeuroDiscovery Lab Research Base in Cambridge, Mass.
3/3/2021
Mitsubishi Tanabe Pharma America, Inc. announced that Mitsubishi Tanabe Pharma Holdings America, Inc. plans to establish a new NeuroDiscovery Lab in the U.S. biotechnology hub of Cambridge, Mass.
-
Mitsubishi Tanabe Pharma America Celebrates Five Years of Dedication to the ALS Community in the U.S.
2/8/2021
Mitsubishi Tanabe Pharma America, Inc. celebrated its five-year anniversary of being established in the United States in 2016.